Patrick Y. Wen

86.9k total citations · 22 hit papers
781 papers, 43.2k citations indexed

About

Patrick Y. Wen is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Patrick Y. Wen has authored 781 papers receiving a total of 43.2k indexed citations (citations by other indexed papers that have themselves been cited), including 588 papers in Genetics, 237 papers in Pulmonary and Respiratory Medicine and 203 papers in Oncology. Recurrent topics in Patrick Y. Wen's work include Glioma Diagnosis and Treatment (585 papers), Brain Metastases and Treatment (173 papers) and Cancer, Hypoxia, and Metabolism (98 papers). Patrick Y. Wen is often cited by papers focused on Glioma Diagnosis and Treatment (585 papers), Brain Metastases and Treatment (173 papers) and Cancer, Hypoxia, and Metabolism (98 papers). Patrick Y. Wen collaborates with scholars based in United States, Switzerland and Netherlands. Patrick Y. Wen's co-authors include Santosh Kesari, David A. Reardon, Timothy F. Cloughesy, Eudocia Q. Lee, Andrew D. Norden, Jan Drappatz, David Schiff, Martin J. van den Bent, Susan M. Chang and Lakshmi Nayak and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Physical Review Letters.

In The Last Decade

Patrick Y. Wen

762 papers receiving 42.4k citations

Hit Papers

Malignant Gliomas in Adults 1995 2026 2005 2015 2008 2010 2009 2011 2015 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Malignant Gliomas in Adults
    2008 3.3k citations Patrick Y. Wen, Santosh Kesari profile →
  2. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
    2010 2.7k citations Patrick Y. Wen, David A. Reardon et al. Journal of Clinical Oncology profile →
  3. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    2009 1.9k citations Henry S. Friedman, Michael D. Prados et al. Journal of Clinical Oncology profile →
  4. Epidemiology of Brain Metastases
    2011 942 citations Patrick Y. Wen et al. profile →
  5. Glioma
    2015 792 citations Patrick Y. Wen et al. profile →
  6. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
    2017 607 citations Patrick Y. Wen et al. Journal of Clinical Oncology profile →
  7. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors [RETIRED]
    2000 537 citations Patrick Y. Wen et al. Neurology profile →
  8. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
    2017 500 citations Patrick Y. Wen, Brian M. Alexander et al. profile →
  9. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
    2015 471 citations Mark R. Gilbert, Benjamin M. Ellingson et al. profile →
  10. Molecular targeted therapy of glioblastoma
    2019 466 citations David A. Reardon, Martin J. van den Bent et al. profile →
  11. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
    2014 465 citations David Schiff, Patrick Y. Wen et al. profile →
  12. Stereotactic Radiosurgery for the Definitive, Noninvasive Treatment of Brain Metastases
    1995 447 citations Patrick Y. Wen, Jay S. Loeffler et al. profile →
  13. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
    2015 433 citations John de Groot, Patrick Y. Wen et al. profile →
  14. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
    2020 314 citations Patrick Y. Wen et al. profile →
  15. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
    2017 295 citations Benjamin M. Ellingson, Patrick Y. Wen et al. profile →
  16. Response Assessment in Neuro-Oncology Clinical Trials
    2017 279 citations Patrick Y. Wen, Susan M. Chang et al. Journal of Clinical Oncology profile →
  17. Epidemiology of brain metastases and leptomeningeal disease
    2021 203 citations Patrick Y. Wen et al. profile →
  18. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
    2022 183 citations Patrick Y. Wen et al. profile →
  19. Glioma
    2024 173 citations Patrick Y. Wen, Susan M. Chang et al. profile →
  20. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
    2022 163 citations Patrick Y. Wen et al. profile →
  21. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas
    2022 156 citations Patrick Y. Wen et al. profile →
  22. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    2023 111 citations Patrick Y. Wen, Elizabeth A. Maher et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick Y. Wen 23.9k 12.3k 11.6k 9.9k 8.0k 781 43.2k
Jill S. Barnholtz‐Sloan 19.6k 0.8× 11.6k 0.9× 9.3k 0.8× 7.1k 0.7× 7.6k 1.0× 435 41.2k
Roger Stupp 31.2k 1.3× 15.7k 1.3× 13.9k 1.2× 9.5k 1.0× 10.7k 1.3× 376 49.8k
Alba A. Brandes 23.6k 1.0× 10.1k 0.8× 9.7k 0.8× 6.6k 0.7× 7.5k 0.9× 359 34.1k
Martin J. van den Bent 35.2k 1.5× 12.7k 1.0× 14.9k 1.3× 8.1k 0.8× 9.9k 1.2× 579 51.0k
David A. Reardon 20.8k 0.9× 10.4k 0.8× 7.3k 0.6× 8.7k 0.9× 7.2k 0.9× 560 34.0k
J. Gregory Cairncross 24.9k 1.0× 12.5k 1.0× 9.4k 0.8× 5.9k 0.6× 8.4k 1.1× 169 36.1k
Warren Mason 20.5k 0.9× 10.6k 0.9× 7.6k 0.7× 5.7k 0.6× 6.8k 0.9× 219 33.3k
Guido Reifenberger 29.1k 1.2× 18.3k 1.5× 8.9k 0.8× 5.8k 0.6× 12.3k 1.5× 354 47.6k
Henry S. Friedman 21.5k 0.9× 15.0k 1.2× 7.9k 0.7× 9.0k 0.9× 7.5k 0.9× 567 38.4k
Thierry Gorlia 20.6k 0.9× 10.3k 0.8× 8.1k 0.7× 5.4k 0.5× 7.3k 0.9× 158 31.2k

Countries citing papers authored by Patrick Y. Wen

Since Specialization
Citations

This map shows the geographic impact of Patrick Y. Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Y. Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Y. Wen more than expected).

Fields of papers citing papers by Patrick Y. Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Y. Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Y. Wen. The network helps show where Patrick Y. Wen may publish in the future.

Co-authorship network of co-authors of Patrick Y. Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Y. Wen. A scholar is included among the top collaborators of Patrick Y. Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Y. Wen. Patrick Y. Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lassman, Andrew B., Patrick Y. Wen, Martin J. van den Bent, et al.. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research. 28(3). 452–460. 40 indexed citations
2.
Ellingson, Benjamin M., Jingwen Yao, Catalina Raymond, et al.. (2020). Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research. 26(13). 3135–3144. 10 indexed citations
3.
Li, Xiaolong, Emmanuel Martínez-Ledesma, Chen Zhang, et al.. (2019). Tie2–FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Research. 79(19). 5088–5101. 20 indexed citations
4.
Ventz, Steffen, Albert Lai, Timothy F. Cloughesy, et al.. (2019). Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clinical Cancer Research. 25(16). 4993–5001. 52 indexed citations
5.
Curry, William T., Matthias Piesche, Tetsuro Sasada, et al.. (2016). Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clinical Cancer Research. 22(12). 2885–2896. 45 indexed citations
6.
Verreault, Maïté, Charlotte Schmitt, Lauriane Goldwirt, et al.. (2015). Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas. Clinical Cancer Research. 22(5). 1185–1196. 81 indexed citations
7.
Reardon, David A., Prafulla C. Gokhale, Sarah R. Klein, et al.. (2015). Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research. 4(2). 124–135. 302 indexed citations
8.
Reardon, David A., Morris D. Groves, Patrick Y. Wen, et al.. (2013). A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research. 19(4). 900–908. 91 indexed citations
9.
Groot, John de, Kathleen R. Lamborn, Susan M. Chang, et al.. (2011). Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology. 29(19). 2689–2695. 168 indexed citations
10.
Groot, John de, Yuji Piao, Hai T. Tran, et al.. (2011). Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research. 17(14). 4872–4881. 51 indexed citations
11.
Sorensen, A. Gregory, Kyrre E. Emblem, Pavlina Polaskova, et al.. (2011). Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Research. 72(2). 402–407. 241 indexed citations
12.
Tomaso, Emmanuelle di, Matija Snuderl, Walid S. Kamoun, et al.. (2011). Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape. Cancer Research. 71(1). 19–28. 156 indexed citations
13.
Batchelor, Tracy T., Dan G. Duda, Emmanuelle di Tomaso, et al.. (2010). Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology. 28(17). 2817–2823. 406 indexed citations
14.
Friedman, Henry S., Michael D. Prados, Patrick Y. Wen, et al.. (2009). Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 27(28). 4733–4740. 1855 indexed citations breakdown →
15.
Sorensen, A. Gregory, Tracy T. Batchelor, Weiting Zhang, et al.. (2009). A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Research. 69(13). 5296–5300. 291 indexed citations
16.
Schiff, David, et al.. (2008). Cancer Neurology In Clinical Practice. Humana Press eBooks. 14 indexed citations
17.
Haining, W. Nicholas, Jeffrey K. Davies, Holger Kanzler, et al.. (2008). CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans. Clinical Cancer Research. 14(17). 5626–5634. 61 indexed citations
18.
Maher, Elizabeth A., Cameron Brennan, Patrick Y. Wen, et al.. (2006). Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities. Cancer Research. 66(23). 11502–11513. 140 indexed citations
19.
Kesari, Santosh, et al.. (2005). January 11 Highlight and Commentary. Neurology. 64(1). 1–1. 7 indexed citations
20.
Lassman, Andrew B., Michael R. Rossi, Lauren E. Abrey, et al.. (2005). Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research. 11(21). 7841–7850. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jill S. Barnholtz‐Sloan Breakdown of academic impact, for papers by Roger Stupp Breakdown of academic impact, for papers by Alba A. Brandes Breakdown of academic impact, for papers by Martin J. van den Bent Breakdown of academic impact, for papers by David A. Reardon Breakdown of academic impact, for papers by J. Gregory Cairncross Breakdown of academic impact, for papers by Warren Mason Breakdown of academic impact, for papers by Guido Reifenberger Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Thierry Gorlia
Rankless by CCL
2026